HealthPartners Institute for Education and Research, and Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota; the Department of Obstetrics and Gynecology, Yale University, New Haven, Connecticut; Northwest Kaiser Permanente, Portland, Oregon; the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts; and Kaiser Permanente Institute for Health Research, and Denver Health Community Health Services, Denver, Colorado.
Corresponding author: James D. Nordin, MD, MPH, HealthPartners Institute for Education and Research, PO Box 1524, MS 21111R, Minneapolis, MN 55425; email: [email protected].
Supported by a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the Centers for Disease Control and Prevention.
The authors thank Beth Molitor, MBA, Leslie Kuckler, MPH, Rachel Gold, PhD, MPH, Karen Riedlinger, MPH, and Samantha Kurosky, MPH, for their assistance with data collection, and Mary VanBeusekom for her assistance in editing the manuscript.
Financial Disclosure Dr. Nichol has served on medical advisory boards for influenza vaccine manufacturers, including MedImmune, Sanofi Pasteur, GlaxoSmithKline, and Novartis. Dr. Naleway has received research funding from GlaxoSmithKline. The other authors did not report any potential conflicts of interest.